Blazing the trail for innovative tuberculosis diagnostics.

Publication date: Nov 30, 2023

The COVID-19 pandemic brought diagnostics into the spotlight in an unprecedented way not only for case management but also for population health, surveillance, and monitoring. The industry saw notable levels of investment and accelerated research which sparked a wave of innovation. Simple non-invasive sampling methods such as nasal swabs have become widely used in settings ranging from tertiary hospitals to the community. Self-testing has also been adopted as standard practice using not only conventional lateral flow tests but novel and affordable point-of-care molecular diagnostics. The use of new technologies, including artificial intelligence-based diagnostics, have rapidly expanded in the clinical setting. The capacity for next-generation sequencing and acceptance of digital health has significantly increased. However, 4 years after the pandemic started, the market for SARS-CoV-2 tests is saturated, and developers may benefit from leveraging their innovations for other diseases; tuberculosis (TB) is a worthwhile portfolio expansion for diagnostics developers given the extremely high disease burden, supportive environment from not-for-profit initiatives and governments, and the urgent need to overcome the long-standing dearth of innovation in the TB diagnostics field. In exchange, the current challenges in TB detection may be resolved by adopting enhanced swab-based molecular methods, instrument-based, higher sensitivity antigen detection technologies, and/or artificial intelligence-based digital health technologies developed for COVID-19. The aim of this article is to review how such innovative approaches for COVID-19 diagnosis can be applied to TB to have a comparable impact.

Open Access PDF

Concepts Keywords
4years COVID-19
Antigen Diagnostics
Hospitals Innovation
Innovation Technology
Tuberculosis Tuberculosis

Semantics

Type Source Name
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease MESH COVID-19 pandemic
disease VO population
disease MESH Infection
disease VO organization
disease MESH AIDS
drug DRUGBANK Nonoxynol-9
disease VO USA
disease MESH emergency
drug DRUGBANK Gold
disease VO effective
drug DRUGBANK Ademetionine
drug DRUGBANK Trestolone
drug DRUGBANK L-Valine
disease VO effectiveness
disease IDO pathogen
drug DRUGBANK Silicon
disease VO viable
disease VO time
disease IDO algorithm
disease VO Gap
disease MESH missed diagnosis
drug DRUGBANK Stavudine
disease IDO drug susceptibility
disease VO volume
drug DRUGBANK Tretamine
drug DRUGBANK Coenzyme M
disease IDO country
disease VO ineffective
drug DRUGBANK Dihydrostreptomycin
drug DRUGBANK Guanine
disease VO storage
disease VO protocol
disease VO nose
disease VO efficient
drug DRUGBANK Medical air
disease IDO blood
disease IDO host
disease IDO cell
drug DRUGBANK Rifampicin
disease IDO facility
disease IDO susceptibility
disease VO company
disease VO device
disease IDO assay
drug DRUGBANK Silver
disease MESH morbidity
drug DRUGBANK Etoperidone
drug DRUGBANK Spinosad
disease IDO production
disease IDO entity
pathway REACTOME Reproduction
disease MESH viral shedding
disease MESH infectious diseases
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH pneumonias
disease VO report
disease MESH Allergy
disease VO Mycobacterium tuberculosis
disease MESH pulmonary tuberculosis
drug DRUGBANK Azelaic acid
drug DRUGBANK Ilex paraguariensis leaf
drug DRUGBANK Guanosine
disease MESH influenza
drug DRUGBANK L-Tyrosine

Original Article

(Visited 1 times, 1 visits today)